DK2515900T3 - Fremgangsmåde til behandling af atriefibrillation - Google Patents
Fremgangsmåde til behandling af atriefibrillation Download PDFInfo
- Publication number
- DK2515900T3 DK2515900T3 DK10798436.1T DK10798436T DK2515900T3 DK 2515900 T3 DK2515900 T3 DK 2515900T3 DK 10798436 T DK10798436 T DK 10798436T DK 2515900 T3 DK2515900 T3 DK 2515900T3
- Authority
- DK
- Denmark
- Prior art keywords
- ranolazine
- dronedarone
- atrial
- approx
- ventricular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Claims (17)
- FREMGANGSMÅDE TIL BEHANDLING AF ATRIEFIBRILLATION1. Ranolazin til anvendelse i en fremgangsmåde til behandling eller forebyggelse af atriefibrillation eller atrieflagren hos en human patient med behov derfor, hvilken fremgangsmåde omfatter administration til patienten af en terapeutisk effektiv mængde af dronedaron eller et farmaceutisk acceptabelt salt deraf og en terapeutisk effektiv mængde ranolazin
- 2. Ranolazin til anvendelse ifølge krav 1, hvor dronedaron eller saltet deraf og ranolazin administreres separat eller sammen som en kombineret doseringsenhed, hvor den kombinerede doseringsenhed fortrinsvis er en tablet.
- 3. Ranolazin til anvendelse ifølge krav 1, hvor dronedaron eller saltet deraf og ranolazin administreres intravenøst eller oralt.
- 4. Ranolazin til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor mængden af administreret ranolazin er fra ca. 50 mg til ca. 3000 mg dagligt, fortrinsvis fra ca. 50 mg til ca. 1500 mg dagligt.
- 5. Ranolazin til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor mængden af administreret dronedaron eller saltet deraf er fra ca. 50 mg til ca. 800 mg dagligt, fortrinsvis fra ca. 50 mg til ca. 600 mg dagligt og mere fortrinsvis fra ca. 50 mg til ca. 400 mg dagligt.
- 6. Ranolazin til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor mængden af administreret dronedaron eller saltet deraf er fra ca. 50 mg til ca. 300 mg dagligt, og mængden af administreret ranolazin er fra ca. 300 mg til ca. 1000 mg dagligt.
- 7. Ranolazin til anvendelse ifølge krav 6, hvor mængden af administreret dronedaron eller saltet deraf er fra ca. 50 mg til ca. 200 mg dagligt.
- 8. Ranolazin til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor saltet af dronedaron er dronedaronhydrochlorid.
- 9. Farmaceutisk formulering omfattende ranolazin og dronedaron eller et farmaceutisk acceptabelt salt deraf og en farmaceutisk acceptabel bærer.
- 10. Farmaceutisk formulering ifølge krav 9, der er formuleret til intravenøs administration eller oral administration.
- 11. Farmaceutisk formulering ifølge krav 9, hvor formuleringen er i en tabletform eller en kapselform.
- 12. Formulering ifølge krav 11, hvor tabletten eller kapslen omfatter fra ca. 25 mg til ca. 600 mg, fortrinsvis fra ca. 50 mg til ca. 200 mg dronedaron eller saltet deraf.
- 13. Formulering ifølge krav 11 eller 12, hvor tabletten eller kapslen omfatter fra ca. 50 mg til ca. 1000 mg, fortrinsvis fra ca. 100 mg til ca. 750 mg ranolazin.
- 14. Formulering ifølge krav 11, hvor tabletten eller kapslen omfatter fra ca. 100 mg til ca. 750 mg ranolazin og ca. 50 mg til ca. 200 mg dronedaron eller saltet deraf.
- 15. Formulering ifølge et hvilket som helst af kravene 9-14, hvor saltet af dronedaron er dronedaronhydrochlorid.
- 16. Formulering ifølge et hvilket som helst af kravene 9-15, hvor ranolazin er formuleret som depotmedicin.
- 17. Formulering ifølge et hvilket som helst af kravene 9-15, hvor dronedaron eller saltet deraf er formuleret til øjeblikkelig frigivelse eller depotmedicin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28873909P | 2009-12-21 | 2009-12-21 | |
PCT/US2010/061257 WO2011084733A1 (en) | 2009-12-21 | 2010-12-20 | Method of treating atrial fibrillation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2515900T3 true DK2515900T3 (da) | 2015-07-27 |
Family
ID=43736345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10798436.1T DK2515900T3 (da) | 2009-12-21 | 2010-12-20 | Fremgangsmåde til behandling af atriefibrillation |
Country Status (37)
Country | Link |
---|---|
US (3) | US8513254B2 (da) |
EP (2) | EP2515900B1 (da) |
JP (2) | JP5723889B2 (da) |
KR (2) | KR20120107995A (da) |
CN (3) | CN102665713B (da) |
AP (1) | AP3536A (da) |
AR (1) | AR079552A1 (da) |
AU (1) | AU2010339753B2 (da) |
BR (1) | BR112012015499A2 (da) |
CA (1) | CA2784028C (da) |
CL (1) | CL2012001597A1 (da) |
CR (1) | CR20120353A (da) |
CY (1) | CY1116511T1 (da) |
DK (1) | DK2515900T3 (da) |
EA (2) | EA025445B1 (da) |
EC (1) | ECSP12012004A (da) |
ES (2) | ES2540093T3 (da) |
HK (1) | HK1170675A1 (da) |
HR (1) | HRP20150644T1 (da) |
HU (1) | HUE026916T2 (da) |
IL (1) | IL220152A (da) |
ME (1) | ME02179B (da) |
MX (2) | MX2012007052A (da) |
NO (1) | NO2749282T3 (da) |
NZ (2) | NZ627181A (da) |
PE (1) | PE20121520A1 (da) |
PL (2) | PL2749282T3 (da) |
PT (2) | PT2749282T (da) |
RS (1) | RS54118B1 (da) |
SG (3) | SG181541A1 (da) |
SI (2) | SI2515900T1 (da) |
SM (1) | SMT201500171B (da) |
TW (1) | TWI508726B (da) |
UA (1) | UA109887C2 (da) |
UY (1) | UY33119A (da) |
WO (1) | WO2011084733A1 (da) |
ZA (1) | ZA201204608B (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4546824B2 (ja) | 2002-05-21 | 2010-09-22 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を処置する方法 |
AU2010276537B2 (en) | 2009-07-27 | 2015-04-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
EP3760180A3 (en) | 2009-07-29 | 2021-01-20 | ICU Medical, Inc. | Fluid transfer devices and methods of use |
WO2011135582A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
TWI510480B (zh) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | 充當離子通道調節劑之稠合雜環化合物 |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (da) | 2011-07-01 | 2018-04-28 | ||
WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
WO2014179764A1 (en) * | 2013-05-03 | 2014-11-06 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
AU2014296378B2 (en) * | 2013-08-02 | 2017-03-30 | Gilead Sciences, Inc. | Pharmaceutical compositions of ranolazine and dronedarone |
WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
US9416128B2 (en) | 2013-12-19 | 2016-08-16 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
CN104951870B (zh) * | 2015-06-01 | 2018-11-13 | 南通科瑞斯生物医药科技有限公司 | 药物临床前心脏风险评估方法 |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ, インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
US10575744B2 (en) | 2017-02-24 | 2020-03-03 | Medtronic Cryocath Lp | Pericardial balloon mapping |
US10799703B2 (en) * | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
EP3530182B1 (en) * | 2018-02-27 | 2020-12-09 | Nokia Technologies Oy | Apparatus and method for determining a change in left ventricular twist of a subject's heart |
US11865186B2 (en) * | 2019-01-24 | 2024-01-09 | Northwestern University | Gene therapy treatment of atrial fibrillation |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
ATE223218T1 (de) | 1989-06-23 | 2002-09-15 | Syntex Llc | Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur |
FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
FR2764800B1 (fr) | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
WO2002009761A2 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
FR2817750B1 (fr) | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
DE60117857D1 (de) | 2000-12-27 | 2006-05-04 | Genzyme Corp | Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen |
WO2003009839A1 (en) * | 2001-07-20 | 2003-02-06 | Karo Bio Ab | Benzofuranes and their use in the treatment of atrial fibrillation |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
JP2008526879A (ja) | 2005-01-06 | 2008-07-24 | シーブイ・セラピューティクス・インコーポレイテッド | ラノラジンを含有する徐放性薬学的処方物 |
WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
CA2678272A1 (en) * | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
JP2012502047A (ja) | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ, インコーポレイテッド | 心房細動を治療する方法 |
-
2010
- 2010-12-16 TW TW099144230A patent/TWI508726B/zh not_active IP Right Cessation
- 2010-12-20 PT PT141613000T patent/PT2749282T/pt unknown
- 2010-12-20 UA UAA201208208A patent/UA109887C2/uk unknown
- 2010-12-20 ME MEP-2015-113A patent/ME02179B/me unknown
- 2010-12-20 CN CN201080058336.3A patent/CN102665713B/zh not_active Expired - Fee Related
- 2010-12-20 BR BR112012015499A patent/BR112012015499A2/pt not_active IP Right Cessation
- 2010-12-20 WO PCT/US2010/061257 patent/WO2011084733A1/en active Application Filing
- 2010-12-20 NZ NZ627181A patent/NZ627181A/en not_active IP Right Cessation
- 2010-12-20 SG SG2012041638A patent/SG181541A1/en unknown
- 2010-12-20 SI SI201030949T patent/SI2515900T1/sl unknown
- 2010-12-20 EP EP20100798436 patent/EP2515900B1/en active Active
- 2010-12-20 NZ NZ600718A patent/NZ600718A/en not_active IP Right Cessation
- 2010-12-20 DK DK10798436.1T patent/DK2515900T3/da active
- 2010-12-20 NO NO14161300A patent/NO2749282T3/no unknown
- 2010-12-20 MX MX2012007052A patent/MX2012007052A/es active IP Right Grant
- 2010-12-20 AR ARP100104774A patent/AR079552A1/es unknown
- 2010-12-20 SG SG10201710751TA patent/SG10201710751TA/en unknown
- 2010-12-20 AP AP2012006331A patent/AP3536A/xx active
- 2010-12-20 EA EA201290451A patent/EA025445B1/ru not_active IP Right Cessation
- 2010-12-20 CN CN201410377525.7A patent/CN104147010A/zh active Pending
- 2010-12-20 PE PE2012000852A patent/PE20121520A1/es active IP Right Grant
- 2010-12-20 CN CN201510028705.9A patent/CN104688739A/zh active Pending
- 2010-12-20 HU HUE10798436A patent/HUE026916T2/en unknown
- 2010-12-20 RS RS20150489A patent/RS54118B1/en unknown
- 2010-12-20 AU AU2010339753A patent/AU2010339753B2/en not_active Ceased
- 2010-12-20 PL PL14161300T patent/PL2749282T3/pl unknown
- 2010-12-20 ES ES10798436.1T patent/ES2540093T3/es active Active
- 2010-12-20 EA EA201691336A patent/EA201691336A1/ru unknown
- 2010-12-20 SI SI201031571T patent/SI2749282T1/sl unknown
- 2010-12-20 PT PT107984361T patent/PT2515900E/pt unknown
- 2010-12-20 JP JP2012544937A patent/JP5723889B2/ja active Active
- 2010-12-20 EP EP14161300.0A patent/EP2749282B1/en active Active
- 2010-12-20 SG SG10201408528RA patent/SG10201408528RA/en unknown
- 2010-12-20 MX MX2014002642A patent/MX344329B/es unknown
- 2010-12-20 CA CA2784028A patent/CA2784028C/en not_active Expired - Fee Related
- 2010-12-20 UY UY33119A patent/UY33119A/xx not_active Application Discontinuation
- 2010-12-20 KR KR1020127018477A patent/KR20120107995A/ko active Application Filing
- 2010-12-20 PL PL10798436T patent/PL2515900T3/pl unknown
- 2010-12-20 US US12/972,949 patent/US8513254B2/en not_active Expired - Fee Related
- 2010-12-20 ES ES14161300.0T patent/ES2646603T3/es active Active
- 2010-12-20 KR KR1020167024642A patent/KR20160108611A/ko not_active Application Discontinuation
-
2012
- 2012-06-04 IL IL220152A patent/IL220152A/en not_active IP Right Cessation
- 2012-06-14 CL CL2012001597A patent/CL2012001597A1/es unknown
- 2012-06-21 ZA ZA2012/04608A patent/ZA201204608B/en unknown
- 2012-06-27 EC ECSP12012004 patent/ECSP12012004A/es unknown
- 2012-06-27 CR CR20120353A patent/CR20120353A/es not_active Application Discontinuation
- 2012-11-13 HK HK12111501.5A patent/HK1170675A1/xx not_active IP Right Cessation
-
2013
- 2013-05-31 US US13/907,349 patent/US8754087B2/en not_active Expired - Fee Related
-
2014
- 2014-03-20 US US14/221,014 patent/US9056108B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258433A patent/JP2015057449A/ja not_active Withdrawn
-
2015
- 2015-06-15 HR HRP20150644TT patent/HRP20150644T1/hr unknown
- 2015-07-14 SM SM201500171T patent/SMT201500171B/xx unknown
- 2015-07-17 CY CY20151100625T patent/CY1116511T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2515900T3 (da) | Fremgangsmåde til behandling af atriefibrillation | |
US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
Singh | Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction | |
KR20110042344A (ko) | 뇌졸중 또는 일과성 허혈 발작을 예방하기 위한 약제의 제조에서의 드로네다론의 용도 | |
US20110166221A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion | |
Advani et al. | Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol | |
AU2014274638B2 (en) | Method of treating atrial fibrillation | |
US20140364417A1 (en) | Method of treating atrial fibrillation |